# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

## **SCHEDULE 13G/A**

## Under the Securities Exchange Act of 1934 (Amendment No. 2)\*

# **Corbus Pharmaceuticals Holdings, Inc.**

(Name of Issuer)

Common Stock

(Title of Class of Securities)

21833P301

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSONS						
1	Cormorant Asset Management, LP						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) ⊠						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
		5	SOLE VOTING POWER 0				
S BEN	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER 2,375,000				
RE			SOLE DISPOSITIVE POWER 0				
	WIIH	8	SHARED DISPOSITIVE POWER 2,375,000				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
9	2,375,000						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.50%						
12	TYPE OF REPORTING PERSON IA						

1	NAME OF REPORTING PERSONS						
	Bihua Chen						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) ⊠						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	United States						
	MBER OF	5	SOLE VOTING POWER				
NU			0				
S	HARES	6	SHARED VOTING POWER				
OV	EFICIALLY VNED BY	0	2,375,000				
	EACH PORTING	7	SOLE DISPOSITIVE POWER				
	ERSON WITH		0				
		8	SHARED DISPOSITIVE POWER				
			2,375,000				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	2,375,000						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
11	19.50%						
10	TYPE OF REPORTING PERSON						
12	IN						
	11.1						

#### Item 1. (a) Name of Issuer

Corbus Pharmaceuticals Holdings, Inc.

#### Item 1. (b) Address of Issuer's Principal Executive Offices

500 River Ridge Drive

Norwood, MA 02062

#### Item 2. (a) Names of Person Filing:

Cormorant Asset Management, LP Bihua Chen

This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

### Item 2. (b) Address of Principal Business Office:

200 Clarendon Street, 52nd Floor Boston, MA 02116

#### Item 2. (c) Citizenship:

Cormorant Asset Management, LP - Delaware Bihua Chen - United States

#### Item 2. (d) Title of Class of Securities

Common Stock (the "Shares")

#### Item 2. (e) CUSIP No.:

21833P301

CUSIP No. 21833P301

SCHEDULE 13G/A

Page 6 of 9 Pages

## Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) □ Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
- (b)  $\square$  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  $\Box$  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  $\Box$  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  $\boxtimes$  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) 🗆 A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  $\Box$  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) □ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable

CUSIP No. 21833P301

SCHEDULE 13G/A

Page 7 of 9 Pages

#### Item 4. Ownership

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon a statement in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 7, 2024, that there were 12,179,482 shares of voting Common Stock of the Issuer outstanding as of November 4, 2024.

### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

### Item 6. Ownership of More Than Five Percent on Behalf of Another Person

See Item 2. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein. Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.

### Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable.

#### Item 8. Identification and Classification of Members of the Group

Not Applicable.

## Item 9. Notice of Dissolution of Group

# Not Applicable.

## Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024

## Cormorant Asset Management, LP

By: Cormorant Asset Management GP, LLC its General Partner

By: /s/ Bihua Chen

Bihua Chen, Managing Member

## Bihua Chen

By: <u>/s/ Bihua Chen</u> Bihua Chen Exhibit I

## JOINT FILING STATEMENT

## PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: November 14, 2024

#### **Cormorant Asset Management, LP**

By: Cormorant Asset Management GP, LLC its General Partner

By: /s/ Bihua Chen

Bihua Chen, Managing Member

Bihua Chen

By: /s/ Bihua Chen Bihua Chen